Fisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant.
|
|
- Owen Bell
- 6 years ago
- Views:
Transcription
1 BJUI A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol Angus Lecuona and Chris F. Heyns Department of Urology, Tygerberg Hospital and University of Stellenbosch, Western Cape, South Africa Accepted for publication 21 July 2010 Study Type Diagnostic (RCT) Level of Evidence 1b OBJECTIVE To compare prostate cancer detection rates using the Vienna nomogram versus an 8-core prostate biopsy protocol. To compare the complication rates of transrectal prostate biopsy in the two groups. PATIENTS AND METHODS In a prospective randomized trial, men with a serum PSA 2.5 ng/ml were stratified according to serum PSA (I = PSA ; II = PSA ; III = PSA ng/ml) and were then randomized to group A (number of cores determined according to the Vienna nomogram) or group B (8-core prostate biopsy). Statistical analysis was performed using Student s t-test for parametric data, Mann- Whitney test for nonparametric data and What s known on the subject? and What does the study add? Several studies have shown that increasing the number of prostate biopsy cores will increase the detection rate of prostate cancer, but also risks overdiagnosing insignificant cancer, particularly in the elderly. Our study suggests that there is no significant advantage in using the Vienna nomogram to determine the number of prostate biopsies to be taken, compared to an eight-core biopsy protocol. Fisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant. RESULTS In the period July 2006 to July 2009, 303 patients were randomized to group A (n = 152) or group B (n = 151). There were no significant differences in serum PSA, prostate volume, PSA density or post-biopsy complications between the groups. The cancer detection rate was lower in group A than in group B for the whole study cohort (35.5% vs 38.4%), for those with PSA < 10 ng/ml (28.1% vs 33%) and for those with prostate volume >50 ml (22% vs 25.8%). These differences were not statistically significant (NSS). CONCLUSION These findings suggest that there is no significant advantage in using the Vienna nomogram to determine the number of prostate biopsy cores to be taken, compared to an 8-core biopsy protocol. KEYWORDS prostate cancer, prostate biopsy, Vienna nomogram INTRODUCTION With the introduction of PSA measurements and the availability of TRUS the optimal number of prostate biopsy cores has become controversial. Several studies have been performed to determine the best prostate biopsy protocol for detecting clinically significant cancer. Increasing the number of biopsy cores increases detection rates [1,2], but risks over-diagnosing insignificant cancers, and it may increase the risk of complications, whereas taking too few biopsy cores will lead to significant cancers being missed. Prostate volume is an important consideration, because too few biopsies in large prostates may fail to diagnose significant cancer [3 5]. Studies have shown that standard sextant (six-core) biopsies may be inadequate [1,3,5 7], because repeat biopsies yield cancer in a further 10 27% of cases [3,6]. A recent study from Vienna [8] proposed using a nomogram to determine the optimal number of TRUS-guided biopsy cores in men with a serum PSA level of 2 10 ng/ml, by taking into account the patient s age and prostate volume. This study compared a group of men who underwent TRUS-guided prostate biopsies according to the Vienna nomogram with a historical group who underwent eight-core biopsies. The group that underwent biopsies according to the Vienna nomogram yielded a significantly higher prostate cancer detection rate of 36.7%, compared with the historical eightcore biopsy group, in which 22% were diagnosed with prostate cancer [8]. The study from Vienna has a few shortcomings. First, it was not a prospective, randomized trial, but compared prospective use of the nomogram with eight-core biopsies obtained in a historical comparison group. The two study groups were not completely comparable with regard to mean age and serum PSA. Second, the study did not compare the risk of complications or adverse events in the two groups, i.e. it is not known whether the greater number of biopsy cores required by the Vienna nomogram results in a higher complication rate , doi: /j x x
2 RCT COMPARING THE VIENNA NOMOGRAM TO 8-CORE PROSTATE BIOPSIES Age (years) Prostate volume (ml) > TABLE 1 The Vienna nomogram [8]: number of biopsy cores based on patient age and total prostate volume were performed under local anaesthesia (periprostatic infiltration of 2% lignocaine). A Toshiba diagnostic ultrasound machine with a 6-MHz transrectal probe was used to instil the anaesthetic and to perform the prostate biopsies. Antibiotic prophylaxis was given 1 h before biopsy using 1 g ciprofloxacin followed by two 500-mg doses at 12-h intervals. TABLE 2 Analysis of whole cohort All study subjects Vienna nomogram Eight-core biopsy P value Patients (n) Age (years) 65.1 (45 82) 63.4 (40 81) * PSA level (ng/ml) 9.4 (2.2 46) 9.2 (2.6 48) Prostate volume (ml) 47.4 (11 220) 51.5 (10 194) PSA density Biopsy cores (n) 10.2 (6 18) 8 Complications, n (%) Any 45 (48.4) 43 (48.9) None 48 (51.6) 45 (51.1) Fever 4 (0.04) 5 (0.06) Urinary retention 1 (0.01) 0 (0) DRE findings Benign 124 (83.2) 115 (76.2) Suspicious or malignant 25 (16.8) 36 (23.8) Histology No prostate cancer 98 (64.5) 93 (61.6) Cancer detected 54 (35.5) 58 (38.4) Data are shown as mean and range (minimum and maximum values), unless otherwise stated. *Statistically significant; fever requiring systemic antibiotics; urinary retention secondary to gross haematuria requiring catheterization and irrigation. Statistical analysis was performed using GRAPHPAD INSTAT software with the unpaired Student s t test for parametric data, Mann Whitney U test for non-parametric data and Fisher s exact test for contingency tables. A two-tailed P-value <0.05 was accepted as significant with a power of 80%. Data are shown as mean and range (minimum and maximum values). Sample size calculation was performed using GRAPHPAD STATMATE software. The study protocol was approved by the Human Research Ethics Committee of the Faculty of Health Sciences of the University of Stellenbosch. RESULTS In the period July 2006 to July 2009, 926 patients underwent prostate biopsies at our unit. After the exclusion criteria were applied, 303 patients were randomized into group A (number of biopsy cores determined according to the Vienna nomogram, n = 152) or group B (eight-core biopsy, n = 151). The aim of our prospective, randomized trial was to determine if the Vienna nomogram would yield a higher cancer detection rate than an eight-core biopsy protocol, without incurring a higher complication rate, in a study population referred to a tertiary urology unit. PATIENTS AND METHODS Patients included in this study were men with a PSA level >2.5 ng/ml undergoing TRUSguided prostate biopsy in the Department of Urology, Tygerberg Hospital, University of Stellenbosch, South Africa. Exclusion criteria included previous prostate biopsy or surgery, previous diagnosis of prostate cancer, a history of urinary retention, previous histological evidence of prostatitis and confirmed urinary tract infection. Patients were stratified according to their serum PSA measurement into those with a low, intermediate or high risk of having prostate cancer (group I, PSA level ng/ ml; group II, ng/ml; group III, ng/ml) and then randomized using computer-generated random numbers: group A underwent TRUS-guided prostate biopsies with the number of cores determined according to the Vienna nomogram (Table 1) and group B underwent an eight-core TRUSguided prostate biopsy. All biopsy cores in both groups were taken from the lateral peripheral zone, evenly distributed from cranial to caudal. The prostate volume was measured by TRUS and biopsies The results of all study subjects and relevant subgroups are summarized in Tables 2 and 3. The mean patient age was slightly but significantly higher in the Vienna nomogram group, but there were no significant differences in serum PSA level, prostate volume, PSA density or post-biopsy complications between the groups. The overall cancer detection rate was higher in the eight-core group (38.4%) than in the Vienna nomogram group (35.5%) but this difference was not significant (NS) (Table 2). The proportion of patients with DRE findings suspicious of malignancy was slightly higher in the eight-core group (23.8% vs 16.8%, NS). This discrepancy may be ascribed to the fact that study subjects were not stratified according to DRE findings before randomization. When controlling for this difference in the subgroup
3 LECUONA and HEYNS of subjects with PSA level <10 ng/ml and benign DRE the cancer detection rate was still higher in the eight-core group (26.9% vs 21.6%; NS). Analysis of different subgroups (PSA level <10 ng/ml, DRE benign plus PSA level <10 ng/ml, prostate volume >50 ml, age <60 or >70 years) showed no significant differences in the cancer detection rates between the Vienna nomogram and eight-core biopsy groups (Table 3) There were no significant differences between the two groups (overall or in any subgroup) as far as complications experienced were concerned. Only minor complications were reported, with self-limiting macroscopic haematuria being the most common. Other complications included haematospermia, haematochezia, dysuria, painful ejaculation and fever. DISCUSSION McNeal [9] described the different zones of the prostate in 1969 and commented on the origin and spread of prostate cancer in the peripheral zone. Hodge et al. [10] introduced systematic sextant biopsy of the prostate under TRUS guidance in These six biopsies were distributed evenly, from cranial to caudal in the mid-lobar, parasagittal plane. Stamey [11] suggested placing these biopsy cores more laterally to better sample the peripheral zone. Several authors have shown that biopsies of the transition zone do not increase cancer detection rates [12]. In 2005, Remzi and colleagues developed the Vienna nomogram (Table 1), using data from the European Prostate Cancer Detection study [3,8]. The nomogram indicates the optimum number of cores to be taken during prostate biopsy, based on patient age and total prostate volume. The objective of the nomogram is to increase prostate cancer detection rates in younger men and those with larger prostates (so decreasing the number of repeat biopsies) and to avoid detection of insignificant cancers in older patients. In a prospective study of 502 men (PSA level 2 10 ng/ml) the overall cancer detection rate was 36.7% [8]. The mean number of cores taken, patient age, total prostate volume and TABLE 3 Analysis of subgroups Vienna nomogram Eight-core biopsy P value Subgroup PSA level <10 ng/ml Age (years) 64.9 (45 79) 62.7 (40 78) * PSA level (ng/ml) 5.8 ( ) 5.7 ( ) Prostate volume (ml) 47.4 (11 220) 46.0 (10 194) PSA density 0.16 ( ) 0.16 ( ) DRE findings, n (%) Benign 102 (91.1) 93 (83.0) Suspicious or malignant 10 (8.9) 19 (17.0) Biopsy cores (n) 10.3 (6 18) 8 No prostate cancer 82 (71.9) 75 (67) Cancer detected 32 (28.1) 37 (33) Subgroup DRE findings benign and PSA level <10 ng/ml No prostate cancer 80 (78.4) 68 (73.1) Cancer detected 22 (21.6) 25 (26.9) Subgroup: prostate volume >50 ml No prostate cancer 39 (78) 46 (74.2) Cancer detected 11 (22) 16 (25.8) Complications, n (%) Any 16 (59.3) 14 (37.8) None 11 (40.7) 23 (62.2) Subgroup: age <60 years No prostate cancer 26 (63.4) 32 (61.5) Cancer detected 15 (36.6) 20 (38.5) Biopsy cores (n) Subgroup: age >70 years No prostate cancer 29 (67.4) 17 (53.1) Cancer detected 14 (32.6) 15 (46.9) Biopsy cores (n) Data are shown as mean and range (minimum and maximum values) unless otherwise stated. *Statistically significant. PSA measurement were 10, 65 years, 43 ml and 5.5 ng/ml, respectively. On multivariate analysis, prostate volume was not an independent predictor of prostate cancer detection, so eliminating the sampling error caused by large prostates by taking more cores. This prospective study also compared well against data from the European Prostate Cancer Detection study [3], where the cancer detection rate was 22% on first biopsy and 10% on repeat biopsy, using an eight-core biopsy. During the study, 926 patients underwent prostate biopsies at our unit, of whom 303 were included. The rationale for excluding patients with UTI, urinary retention or previous prostatic procedures was to exclude those with a falsely raised PSA level. The fact that 623 patients were excluded from the study reflects our referral patient profile, where most men present with advanced prostate cancer disease or complications of BPH such as UTI or retention. In the present study the cancer detection rate was higher in the eight-core biopsy group than in the Vienna nomogram group for the whole study cohort (38.4% vs 35.5%), for those with a PSA reading <10 ng/ml (33%
4 RCT COMPARING THE VIENNA NOMOGRAM TO 8-CORE PROSTATE BIOPSIES versus 28.1%), for those with prostate volume >50 ml (25.8% vs 22%) and for those with both PSA level <10 ng/ml and clinical BPH (26.9% vs 21.6%) (Tables 2 and 3). However, these differences were small and not significant. The mean PSA values of the two groups were 9.4 ng/ml (Vienna nomogram group) vs 9.2 ng/ml (Control group), and reflect all patients with PSA levels between 2.5 and 50 ng/ml. Most patients had a PSA level <10 ng/ml (n = 226; 75%) with a mean of 5.8 ng/ml in the Vienna nomogram group compared with 5.7 ng/ml in the control group. The two groups are comparable in all aspects except age, for which the Vienna nomogram group has a mean age of 64.9 years vs 62.7 years in the control group. This subgroup (PSA level ng/ml) is also comparable to the patients in the original Vienna nomogram article (Table 3). Findings on DRE were more often suspicious of malignancy in the eight-core group than in the Vienna nomogram group for the whole cohort and subgroups. This discrepancy between the two groups occurred by chance, despite stratification according to serum PSA, and probably explains the higher cancer detection rate in group B. However, even when controlling for this, the eightcore biopsy protocol still detected more prostate cancer than the Vienna nomogram group, although the difference was not significant. Several authors have shown that increasing the number of prostate biopsies increases the cancer detection rate [1,13 15]. The use of extended biopsy protocols eventually led to saturation biopsy schemes [6,7], which involve taking cores in one sitting. These biopsy schemes particularly target the lateral peripheral zone and apex of the prostate. As an initial biopsy strategy, Jones et al. [16] did not find saturation biopsies useful. In a cohort of 139 patients who underwent saturation biopsies (24 cores), 44.6% were diagnosed with prostate cancer, compared with a 51.7% detection rate in a historical comparison group (10 cores) consisting of 87 patients. Guichard et al. [17] published a series of 1000 consecutive patients. The cancer detection rates of the 6-, 12-, 18- and 21-core biopsy strategies were 31.7%, 38.7%, 41.5% and 42.5%, respectively, in patients who underwent first-time biopsies. Other authors [18] had similar results of a 40% cancer detection rate, using saturation biopsy techniques for firsttime biopsies. However, saturation biopsies have proven effective when used in the repeat biopsy scenario [19,20]. Recently, concerns have been raised regarding the potential under-sampling of larger glands by the traditional sextant biopsy protocol [3 5]. One of the aims of the Vienna nomogram is to increase prostate cancer detection by increasing the number of cores taken at biopsy of larger prostates (Table 1). In our study, in the subgroup of patients with a prostate volume >50 ml, prostate cancer detection was higher in the eight-core group (25.8%) compared with the Vienna nomogram group (22%; mean number of cores taken 14.4), but this difference was not significant (Table 3). Given the high prevalence of histological prostate cancer [21], the increased detection due to (i) structured screening studies, (ii) a greater awareness of prostate cancer among the general public, (iii) a reduction in PSA thresholds for biopsy, (iv) an increase in the number of biopsy cores [22] and (v) the long lead-time of prostate cancer, the risk of overdiagnosis and overtreatment is substantial [23]. Another aim of the Vienna nomogram is to reduce the likelihood of detecting insignificant prostate cancer, by reducing the number of biopsies taken from older patients. Criteria which could indicate clinically insignificant prostate cancer, and which could be used in active surveillance of patients, include: a Gleason score 6 (no pattern 4 or 5 disease), PSA level 10 ng/ml, clinical stage T1 or T2a disease, PSA density 0.15, percentage positive biopsy cores <33%, <50% involvement of any biopsy core and stable PSA kinetics [24 26]. Using the above definition, only 14 (4.6%) of the 303 patients in our study had insignificant prostate cancer, 5/152 (3.3%) in the Vienna nomogram group and 9/151(6.0%) in the control group. Unfortunately, no conclusions can be drawn from so few patients, except that insignificant prostate cancer is extremely rare in our referral population. In our study, more patients were diagnosed with prostate cancer in the age group >70 years, using the eight-core biopsy protocol compared with the Vienna nomogram (46.9% vs 32.6%; NS). The mean number of cores taken with the Vienna nomogram in patients older than 70 years was 8.5. Increasing the number of prostate biopsy cores raises the concern of increased morbidity. TRUS-guided biopsies of the prostate are associated with several minor but self-limiting complications and are usually well tolerated by patients [27]. In our study the complication rates in the two groups overall were almost identical (Table 2). Patients in the subgroup with prostate volume >50 ml had a higher complication rate in the Vienna nomogram group (average of 14.4 cores) than in the eight-core group (59.3% vs 37.8, NS) (Table 3). These complications were minor, consisting mostly of self-limiting macroscopic haematuria. Serious complications were rare: four patients in the Vienna nomogram group and five patients in the control group developed post-biopsy fever requiring parenteral antibiotic treatment at their local hospital or general practitioner. All patients had an uneventful recovery. One patient in the Vienna nomogram group (16 cores) developed urinary retention secondary to gross haematuria that required catheterization and irrigation for 2 days (Table 2). The main limitation of this study is that stratification before randomization was performed according to serum PSA level alone and did not include DRE, with the result that, by chance, a greater proportion of subjects with DRE findings suspicious of malignancy were included in group B, but controlling for this discrepancy did not reveal a significant difference in cancer detection. The main objective of this prospective, randomized study was to determine whether the Vienna nomogram (which was originally developed in a screening setting) would be useful, when applied in a urology referral unit. Overall, when comparing the results from biopsies taken using the Vienna nomogram versus an eight-core biopsy protocol, no significant differences were noted in the cancer detection or complication rates. CONFLICT OF INTEREST None declared
5 LECUONA and HEYNS REFERENCES 1 Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000; 164: Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163: Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughn ED Jr. The influence of prostate size on cancer detection. Urology 1995; 46: Remzi M, Djavan B, Wammack R et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003; 61: Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000; 163: Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86 91; discussion Remzi M, Fong YK, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174: McNeal JE. Origin and development of carcinoma of the prostate. Cancer 1969; 23: Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: Pelzer AE, Bektic J, Berger AP et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the Tyrol screening project. Eur Urol 2005; 48: Philip J, Ragavan N, Desouza J, Foster CS, Javle P. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. BJU Int 2004; 93: Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: Inahara M, Suzuki H, Kojima S et al. Improved prostate cancer detection using systematic 14-core biopsy for large glands with normal digital rectal examination findings. Urology 2006; 68: Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175: Guichard G, Larré S, Gallina A et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007; 52: Descazeaud A, Rubin M, Chemama S et al. Saturation biopsy protocol enhances prediction of pt3 and surgical margin status on prostatectomy specimen. World J Urol 2006; 24: Walz J, Graefen M, Chun FK et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20 69: an autopsy study of 249 cases. In Vivo 1994; 8: Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: Dall Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer. Cancer 2008; 112: O Donnell H, Parker C. What is low-risk cancer and what is its natural history? World J Urol 2008; 26: Paul R, Schöler S, van Randenborgh H, Kübler H, Alschibaja M, Busch R. Morbidity of prostatic biopsy for different biopsy strategies: is there a relation to core number and sampling region? Eur Urol 2004; 45: Correspondence: Angus Lecuona, Tygerberg Hospital, University of Stellenbosch, Department of Urology, Room th Floor, Clinical Building Faculty of Health Sciences Tygerberg Western Cape 7505, South Africa. anguslecuona@yahoo.com Abbreviation: NS, not significant
BJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationProstate Cancer Detection and High Grade PIN
Clinical Urology Prostate Cancer Detection and High Grade PIN International Braz J Urol Vol. 37 (1): 87-93, January - February, 2011 doi: 10.1590/S1677-55382011000700011 The Implication of Initial 24-Core
More informationProstate cancer diagnosis: should patients with prostate specific antigen >10 ng/ml have stratified prostate biopsy protocols?
Cancer Detection and Prevention 32 (2009) 34 38 www.elsevier.com/locate/cdp Prostate cancer diagnosis: should patients with prostate specific antigen >0 ng/ml have stratified prostate biopsy protocols?
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationTWELVE CORE PROSTATE BIOPSY VERSUS SIX SYSTEMATIC SEXTANT BIOPSIES
Clinical Urology Brazilian Journal of Urology Vol. 28 (3): 207-213, May - June, 2002 Official Journal of the Brazilian Society of Urology TWELVE CORE PROSTATE BIOPSY VERSUS SI SYSTEMATIC SETANT BIOPSIES
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationUltrasound-guided transrectal extended prostate biopsy: a prospective study
DOI: 10.1111/j.1745-7262.2005.00019.x. Original Article. Ultrasound-guided transrectal extended prostate biopsy: a prospective study Mohammed Ahmed Al-Ghazo, Ibrahim Fathi Ghalayini, Ismail Ibrahim Matalka
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationWhat Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?
www.kjurology.org http://dx.doi.org/1.4111/kju.214.55.11.725 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=1.4111/kju.214.55.11.725&domain=pdf&date_stamp=214-11-16 What
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationThe TRUS guided prostate extended biopsy in the detection of prostate cancer
Mædica - a Journal of Clinical Medicine ORIGIN RIGINAL PAPERS The TRUS guided prostate extended biopsy in the detection of prostate cancer Assoc. Prof. V. AMBERT, MD, PhD; A. ATEIA, MD; I. CHIRA, MD, PhD;
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More information, De La Taille Alexandre * INSERM : U955, Universit é Paris XII Val de Marne, IFR10, FR. , Universit é Paris XII Val de Marne, Créteil,FR
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance Ploussard
More informationIndividualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels
DOI: 10.1111/j.1745-7262.2008.00345.x www.asiaandro.com. Clinical Experience. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels Bo Dai 1,4, Ding-Wei
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationHigh Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous Negative Biopsy Series
european urology 50 (2006) 498 505 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer High Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationOriginal Paper. Urol Int 2013;90: DOI: /
Urologia Internationalis Original Paper Received: January 27, 2012 Accepted after revision: November 26, 2012 Published online: February 13, 2013 Comparison of Transrectal Prostate Biopsy Results with
More informationNumber: Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB.
Number: 0698 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers a transperineal stereotactic template guided saturation prostate biopsy medically necessary for
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationCorporate Medical Policy
Corporate Medical Policy Saturation Biopsy for Diagnosis, Staging, and Management of Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_ staging_and_management_of_prostate_cancer
More informationThe In uence of Prostate Volume on Prostate Cancer Detection
European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationSingle Positive Core Prostate Cancer in a 12-Core Transrectal Biopsy Scheme: Clinicopathological Implications Compared with Multifocal Counterpart
www.kjurology.org DOI:10.4111/kju.2010.51.10.671 Urological Oncology Single Positive Core Prostate Cancer in a 12-Core Transrectal Biopsy Scheme: Clinicopathological Implications Compared with Multifocal
More informationBJUI. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology CLINICAL STAGING ERROR IN PROSTATE CANCER BOLENZ et al. BJUI BJU INTERNATIONAL Clinical staging error in prostate cancer: localization and
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationOriginal Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
Int J Clin Exp Pathol 2012;5(9):892-899 www.ijcep.com /ISSN:1936-2625/IJCEP1207013 Original Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationPredictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.10.677 Urological Oncology Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy Seung Jin
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationNomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
Original Article Prostate Int 2013;1(2):69-75 P R O S T A T E INTERNATIONAL Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationThe Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy
Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 834 841 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Optimal Rebiopsy Prostatic Scheme Depends on Patient Clinical Characteristics:
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationOncology: Prostate/Testis/Penis/Urethra
0022-5347/04/1724-1297/0 Vol. 172, 1297 1301, October 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000139993.51181.5d Oncology: Prostate/Testis/Penis/Urethra
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationIs there a role for anterior zone sampling as part of saturation trans-rectal ultrasound guided prostate biopsy?
Cole et al. BMC Urology 2014, 14:34 RESEARCH ARTICLE Open Access Is there a role for anterior zone sampling as part of saturation trans-rectal ultrasound guided prostate biopsy? Eric Cole 1, David Margel
More informationRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
ORIGINAL ARTICLE (2011) 14, 53 57 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan Relationship between initial PSA density with future PSA kinetics and repeat biopsies
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationUpgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
More informationProstate gold seed fiducial implantation by radiation oncologists: A report on feasibility
Prostate gold seed fiducial implantation by radiation oncologists: A report on feasibility Poster No.: R-0006 Congress: Type: Authors: Keywords: DOI: 2014 CSM Scientific Exhibit C. Jayaratne, A. Brown,
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationExtended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the Literature
european urology 52 (2007) 1309 1322 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationMagnetic Resonance Imaging Targeted Biopsy of the Prostate
Magnetic Resonance Imaging Targeted Biopsy of the Prostate Policy Number: 7.01.152 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationProstate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients
ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative
More informationClinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
european urology 54 (2008) 1081 1088 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationThe Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance
EUROPEAN UROLOGY 56 (2009) 891 898 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Nazareno Suardi on pp. 899 900 of this issue
More informationSignificance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
www.kjurology.org http://dx.doi.org/1.4111/kju.211.52.11.736 Urological Oncology Significance of Atypical Small Acinar Proliferation and HighGrade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
More informationGetting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust
Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationCorrelation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results
ORIGINAL ARTICLE Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results Gholamreza Pourmand, Shahram Gooran, Seyed Reza Hossieni,
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationDiagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy
ORIGINAL ARTICLE Diagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy I-Ni Chiang, 1,2 Shang-Jen Chang, 3 Yeong-Shiau Pu, 1,2 Kuo-How Huang, 1,2 Hong-Jen Yu, 1,2
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationThe Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.5.313 Urological Oncology The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy Dae Keun Kim, Sang Jin
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationLocal Recommendations for Active Surveillance of Prostate Cancer
February 15 Local Recommendations for Active Surveillance of Prostate Cancer Chris Dawson Urology Lead Clinician February 2015 www.pchurology.co.uk Summary and Recommendations 1. There is no single set
More information1. Introduction. Department of Urology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba , Japan 2
Hindawi Publishing Corporation Prostate Cancer Volume 2011, Article ID 754382, 6 pages doi:10.1155/2011/754382 Clinical Study Development and External Validation of a Nomogram Predicting the Probability
More informationNIH Public Access Author Manuscript J Urol. Author manuscript; available in PMC 2011 October 16.
NIH Public Access Author Manuscript Published in final edited form as: J Urol. 2011 October ; 186(4): 1281 1285. doi:10.1016/j.juro.2011.05.078. Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate
More informationClinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions
Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions Alexandre de la Taille,*, Jacques Irani, Markus Graefen, Felix Chun, Theo de Reijke, Paul Kil, Paolo Gontero, Alain Mottaz and
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationProstate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict clinically significant prostate cancer
ORIGINAL ARTICLE Vol. 41 (3): 442-448, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0251 Prostate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict
More informationeuropean urology 54 (2008)
european urology 54 (2008) 1354 1362 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography:
More informationDiagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen
ORIGINAL ARTICLE (2009) 12, 137 142 & 2009 Nature Publishing Group All rights reserved 1365-7852/09 $32.00 www.nature.com/pcan for the staging of microfocal prostate cancers in autopsy specimen NB Delongchamps
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More information